Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707124 | 1.00 | KDM1A (0.34) | KDM1ARCOR1MEN1MAPK1HTT | |
| SCHEMBL707400 | 0.78 | CA1 (0.33) | HSD11B1SLC10A2 | |
| SCHEMBL707705 | 0.78 | CA1 (0.33) | HSD11B1SLC10A2 | |
| SCHEMBL3477146 | 0.74 | KDM1A (0.34) | KDM1ARCOR1MEN1MAPK1HTT | |
| SCHEMBL4983556 | 0.74 | KDM1A (0.34) | KDM1ARCOR1MEN1MAPK1HTT | |
| SCHEMBL19385727 | 0.64 | HSD11B1 (0.38) | MEN1KMT2AHSD11B1 | |
| SCHEMBL19385739 | 0.64 | HSD11B1 (0.38) | MEN1KMT2AHSD11B1 | |
| SCHEMBL21065308 | 0.63 | KDM1A (0.44) | KDM1ARCOR1HSD11B1 | |
| SCHEMBL22973669 | 0.63 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL2503657 | 0.62 | RORC (0.40) | KDM1ARCOR1MEN1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124633-B2 | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7683068-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | KDM1A 1697/4885RCOR1 2764/4885MEN1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.